about
Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFbeta expressionCyclophosphamide versus placebo in scleroderma lung disease.The risk of cardiovascular disease in systemic sclerosis: a population-based cohort study.A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phEffects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosisGastric antral vascular ectasia and its clinical correlates in patients with early diffuse systemic sclerosis in the SCOT trial.Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial.B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosisThe clinical significance of liver disease in systemic lupus erythematosus.Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.Durometry for the assessment of skin disease in systemic sclerosis.Controlled trials of therapy in fibromyalgia syndrome.Development of preliminary criteria for response to treatment in fibromyalgia syndrome.The epidemiology of AL and AA amyloidosis.Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients.The Comparative Efficacy of Drug Therapies Used for the Management of Corticosteroid-Induced Osteoporosis: A Meta-RegressionTenderness in 75 anatomic sites. distinguishing fibromyalgia patients from controlsMicrobiome dysbiosis is associated with disease duration and increased inflammatory gene expression in systemic sclerosis skinExcessive fibrinolysis in amyloidosis associated with elevated plasma single-chain urokinaseExtrapulmonary thoracic restriction (hidebound chest) complicating eosinophilic fasciitisBowel dysfunction in fibromyalgia syndromeHigh frequency of fibromyalgia in patients with chronic fatigue seen in a primary care practiceElectrocardiography and Doppler echocardiography in secondary (AA) amyloidosisRelapsing polychondritis and aseptic meningitisRecurrence of primary (AL) amyloidosis in a transplanted heart with four-year survivalFibromyalgia syndrome: current concepts in pathophysiology, clinical features, and managementLack of association between fibromyalgia syndrome and abnormalities in muscle energy metabolismLiver transplantation as a treatment for familial amyloidotic polyneuropathyA study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritisSystemic sclerosis-associated pulmonary hypertension: short- and long-term effects of epoprostenol (prostacyclin)The role of leukotrienes in alveolitis associated with sclerodermaRecombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trialFibromyalgia is not a muscle disorderImpact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung studyRituximab: a potential therapeutic advance in scleroderma: what is the evidence?MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trialDistinct evolution of TLR-mediated dendritic cell cytokine secretion in patients with limited and diffuse cutaneous systemic sclerosis
P50
Q33471458-51868D6E-E00D-459C-A1AA-7C88F1C69D8EQ34540647-65912BAD-4106-4456-8F73-15705FDD44F7Q35283742-4AB70F46-1306-4600-BBB2-643E22529EF5Q35878705-6BED790C-E635-4E0B-90D8-344D512E89A3Q36145795-FF95C7BB-CE25-4988-8CBF-98310B32D26BQ36171822-18F77948-D0F1-4726-A8AE-6F1F92ECA2D2Q36837678-278E68FF-3254-4576-8E5E-A501686B5032Q37013037-AE1710E6-9810-41C6-944F-746131095A76Q37088694-9BBD7969-9651-458B-AF24-33E2F5011EB4Q37349268-A6322523-576E-49BA-BEB9-CD060CFD638BQ39632069-106F041D-8AE1-4059-880C-3188FDD8B6D2Q39702715-00A28BCA-CE1F-4CB3-A722-6CDEC3E8693DQ39763819-AE5D2CCF-0F55-4109-ABE1-F292DE458BB3Q40589781-58D7A19A-EA2E-4E24-9F94-6C795E91664CQ41142131-18F8F3D8-CF8C-406F-9971-87BFA3BA5648Q45230213-2DAD7EC9-7156-4F8C-9E8D-105706234B49Q51033339-C108E1E4-CE41-466E-8E31-A0B0A1D55C10Q52521552-8B73B34A-03FA-4142-9DF3-4240B8065928Q57244887-393AA162-BF8D-4B6E-8745-4ED93830E446Q57244965-3E15AACD-4AB1-4B78-99F3-7DAEA7DD239AQ61798347-8031A53E-8780-4184-9AF8-B4A81F519F6FQ67990982-027EF3A8-12D0-4AB0-AAE5-AE2687A42A43Q68034695-D45B3446-6ED9-4036-BC01-017E8764C0C3Q68177331-1AB351F9-7FF9-4FA4-9118-EA1D063072A6Q68736060-6A68DF62-2FF1-43C0-9ABE-983ABEC6A28CQ71015688-CF17D494-5629-4C41-B4A3-FE2786BCE680Q71595677-D00B5EF7-704E-4EC4-B154-E51AF58EA7A0Q71774378-E2B20BD5-1D63-4EE3-892D-C26BE95B67EAQ71979796-0A0709C2-34B2-407A-90DA-A1F0568F8A28Q71993389-6F5D8577-B9E2-43DD-B7EE-43A81A9B1E59Q72647122-4D45AA6E-7A0F-4DCE-A9F0-C764F7D6BF21Q72718482-874E93E2-9DF7-4B13-8E78-E3DACD8D9920Q73313555-CB9EF202-6345-453E-9A41-7563D98FA720Q73497729-A94A7DD4-F17D-4E10-9BD7-2A0CA8F75D35Q73849049-67968BF4-CC94-404A-9183-1C7FF11C55C1Q74694691-E474DA39-2512-4BBC-8E51-59DE64CFE6BCQ80238470-90FDBAD5-A226-492F-BF6C-2D5374A2C649Q82329917-CA5EF680-E911-4C4A-A4CC-BB509F36F051Q83398948-AE692959-D118-40BE-86FB-045BCFB8D380Q84291407-063B13E4-5069-479E-B6D5-104C7C1FDD9F
P50
description
researcher ORCID ID = 0000-0002-0101-1807
@en
wetenschapper
@nl
name
Robert Simms
@ast
Robert Simms
@en
Robert Simms
@es
Robert Simms
@nl
type
label
Robert Simms
@ast
Robert Simms
@en
Robert Simms
@es
Robert Simms
@nl
prefLabel
Robert Simms
@ast
Robert Simms
@en
Robert Simms
@es
Robert Simms
@nl
P106
P31
P496
0000-0002-0101-1807